Morphine sulfate and naltrexone hydrochloride extended release capsules for the management of chronic, moderate-to-severe pain, while reducing morphine-induced subjective effects upon tampering by crushing

Bibliography

• Chou R, Fanciullo GJ, Fine PG, Opioid treatment guidelines. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10:113-30
   PubMed Web of Science ®Google Scholar
• Coluzzi F, Pappagallo M. Opioid therapy for chronic noncancer pain: practice guidelines for initiation and maintenance of therapy. Minerva Anestesiol 2005;71:425-33
   PubMedGoogle Scholar
• Cherny NI. Opioid analgesics: comparative features and prescribing guidelines. Drugs 1996;51:713-37
   PubMed Web of Science ®Google Scholar
• Atluri S, Boswell M, Hansen H, Guidelines for the use of controlled substances in the management of chronic pain. Pain Physician 2003;6:233-57
   PubMedGoogle Scholar
• American Society of Anesthesiologists Task Force and American Society of Regional Anesthesia and Pain Medicine. Practice guidelines for chronic pain management, an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. Anesthesiology 2010;112:810-33
   PubMedGoogle Scholar
• Pergolizzi J, Boger RH, Budd K, Opioids and the management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used World Health Organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). World Inst Pain 2008;8:287-313
   PubMedGoogle Scholar
• Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med 2003;349:1943-53
   PubMed Web of Science ®Google Scholar
• Schneider JP, Kirsh KL. Defining clinical issues around tolerance, hyperalgesia, and addiction: a quantitative and qualitative outcome study of long-term opioid dosing in a chronic pain practice. J Opioid Manag 2010;6:385-95
   PubMedGoogle Scholar
• American Academy of Pain Medicine/American Pain Society. The use of opioids for the treatment of chronic pain: a consensus statement from the American Academy of Pain Medicine and American Pain Society, 1996. Available from: http://www.ampainsoc.org/advocacy/opioids.htm [Last accessed 8 October 2010]
   Google Scholar
• Kuehn BM. Opioid prescriptions soar: increase in legitimate use as well as abuse. JAMA 2007;297:249-51
   PubMed Web of Science ®Google Scholar
• Kuehn BM. Scientists probe ways to curb opioid abuse without hindering pain treatment. JAMA 2007;297:1965-7
   PubMedGoogle Scholar
• Katz NP, Adams EH, Benneyan JC, Foundations of opioid risk management. Clin J Pain 2007;23:103-18
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health: Volume 1. Summary of National Findings (Office of Applied Studies, NSDUH Series H-38A, HHA Publication No. SMA 10-4586 Findings), 2010. Available from: http://www.oas.samhsa.gov/NSDUH/2k9NSDUH/2k9ResultsP.pdf [Last accessed 8 October 2010]
   Google Scholar
• FDA Consumer Health Information. Combating misuse and abuse of prescription drugs. FDA Consumer Health Information/US Food and Drug Administration. July 2010. Available from: http://www.fda.gov/downloads/ForConsumers/ConsumerUpdates/UCM220434.pdf [Last accessed 8 October 2010]
   Google Scholar
• US Department of Health and Human Services. Emergency department visits involving nonmedical use of selected prescription drugs – United States, 2004 – 2008. Morb Mortal Wkly Rep 2010;59:705-14
   PubMedGoogle Scholar
• Office of National Drug Control Policy Executive Office of the President. Prescription for danger: a report on the troubling trend of prescription and over-the-counter drug abuse among the nation's teens. Office of National Drug Control Policy, Executive Office of the President website. January 2008. Available from: http://www.theantidrug.com/pdfs/prescription_report.pdf [Last accessed 4 May 2009]
   Google Scholar
• McCabe SE, Cranford JA, Boyd CJ, Teter CJ. Motives, diversion and routes of administration associated with nonmedical use of prescription opioids. Addict Behav 2007;32:562-75
   PubMed Web of Science ®Google Scholar
• Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clin Proc 2009;84:593-601
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Outpatient prescription opioid utilization in the US, years 2000 – 2009. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM220950.pdf [Last accessed 14 February 2011]
   Google Scholar
• RADARS system data indicate immediate release opioids responsible for higher proportion of misuse, abuse and diversion than extended release opioids. RADARS Syst News 2009;4(2). Available from: http://www.radars.org/LinkClick.aspx?fileticket=PEUldFIeRps%3D&tabid=1114 [Last accessed 28 March 2011]
   Google Scholar
• Sloan P, Babul N. Extended-release opioids for the management of chronic non-malignant pain. Expert Opin Drug Deliv 2006;3:489-97
   PubMedGoogle Scholar
• Paulozzi LJ. Trends in unintentional drug overdose deaths. US Department of Health and Human Services Testimony before Senate Judiciary Subcommittee on Crime and Drugs. 12 March 2008. Available from: http://www.hhs.gov/asl/testify/2008/03/t20080312b.html [Last accessed 19 May 2010]
   Google Scholar
• Fudala PJ, Johnson RE. Development of opioid formulations with limited diversion and abuse potential. Drug Alcohol Depend 2006;83(Suppl 1):S40-7
   PubMedGoogle Scholar
• Webster LR, Bath B, Medve RA. Opioid formulations in development designed to curtail abuse: who is the target? Expert Opin Investig Drugs 2009;18:255-63
   PubMed Web of Science ®Google Scholar
• Griffiths RR, Bigelow GE, Ator NA. Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend 2003;70:S41-54
   PubMed Web of Science ®Google Scholar
• Embeda [package insert]. Bristol, TN: King Pharmaceuticals, Inc., June 2009
   Google Scholar
• Stauffer J, Setnik B, Sokolowska M, Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study. Clin Drug Investig 2009;29:777-90
   PubMed Web of Science ®Google Scholar
• Johnson FK, Stark JG, Bieberdorf FA, Stauffer J. Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. Clin Ther 2010;32:1149-64
   PubMed Web of Science ®Google Scholar
• ReVia [package insert]. Noble Park, Victoria, Australia: Bristol-Myers Squibb Australia Pty Ltd, July 2002
   Google Scholar
• Johnson FK, Ciric S, Boudriau S, The relative bioavailability of morphine sulfate and naltrexone hydrochloride extended release capsules (EMBEDA) and an extended release morphine sulfate capsule formulation (KADIAN) in healthy adults under fasting conditions. Am J Ther 2011;18:2-8
   PubMed Web of Science ®Google Scholar
• Kadian [package insert]. Morristown, NJ: Actavis Kadian LLC, February 2010
   Google Scholar
• Katz N, Sun S, Johnson F, Stauffer J. ALO-01 (morphine sulfate and naltrexone hydrochloride) extended release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety. J Pain 2010;11:303-11
   PubMed Web of Science ®Google Scholar
• Johnson F, Ciric S, Boudriau S, Food efffects on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules. Adv Ther 2010;27:846-58
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network, 2006: National Estimates of Drug-Related Emergency Department Visits (Office of Applied Studies, DAWN Series D-30, DHHS Publication No. SMA 08-4339), 2008. Available from: http://dawninfo.samhsa.gov/files/ED2006/DAWN2k6ED.pdf [Last accessed 22 April 2009]
   Google Scholar
• Johnson FK, Ciric S, Boudriau S, Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules. J Clin Pharmacol; In press
   Google Scholar
• Cole JO, Orzack MH, Beake B, Assessment of the abuse liability of buspirone in recreational sedative users. J Clin Psychiatry 1982;43:69-74
   PubMed Web of Science ®Google Scholar
• Martin WR, Sloan JW, Sapira JD, Jasinski DR. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 1971;12:245-58
   PubMed Web of Science ®Google Scholar
• Webster L, Jones JB, Johnson F, Relative drug-liking/euphoria effects of intravenous morphine alone and in combination with naltrexone in recreational opioid users. Poster presented at the International Association for the Study of Pain 12th World Congress on Pain, Glasgow, Scotland, UK, 17 August 2008
   Google Scholar
• Katz N, Hale M, Morris D, Stauffer J. Morphine sulfate and naltrexone hydrochloride extended-release capsules in patients with chronic osteoarthritis pain. Postgrad Med 2010;122:112-28
   PubMed Web of Science ®Google Scholar
• Katz N, Rauck R, Ahdieh H, A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. Curr Med Res Opin 2007;23:117-28
   PubMed Web of Science ®Google Scholar
• Hale ME, Dvergsten C, Gimbel J. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study. J Pain 2005;6:21-8
   PubMed Web of Science ®Google Scholar
• Webster LR, Brewer R, Wang C, Long-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain. J Pain Symptom Manage 2010;40:734-46
   PubMed Web of Science ®Google Scholar
• Wallace M, Moulin DE, Rauck RL, Long-term safety, tolerability, and efficacy of OROS hydromorphone in patients with chronic pain. J Opioid Manag 2009;5:97-105
   PubMedGoogle Scholar
• Portenoy RK, Farrar JT, Backonja MM, Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study. Clin J Pain 2007;23:287-99
   PubMed Web of Science ®Google Scholar
• Roth SH, Fleischmann RM, Burch FX, Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation. Arch Intern Med 2000;160:853-60
   PubMed Web of Science ®Google Scholar
• Nicholson B, Ross E, Sasaki J, Weil A. Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain. Curr Med Res Opin 2006;22:1503-14
   PubMed Web of Science ®Google Scholar
• Milligan K, Lanteri-Minet M, Borchert K, Evaluation of long-term efficacy and safety of transdermal fentanyl in the treatment of chronic non-cancer pain. J Pain 2001;2:197-204
   PubMed Web of Science ®Google Scholar
• Dellemijn PL, van Duijn H, Vanneste JA. Prolonged treatment with transdermal fentanyl in neuropathic pain. J Pain Symptom Manage 1998;16:220-9
   PubMed Web of Science ®Google Scholar
• Caldwell JR, Rapoport RJ, Davis JC, Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. J Pain Symptom Manage 2002;23:278-91
   PubMed Web of Science ®Google Scholar
• Allan LG, Rucharz U, Simpson K, Slappendel R. Transdermal fentanyl versus sustained release oral morphine in strong-opioid naive patients with chronic low back pain. Spine 2005;30:2484-90
   PubMed Web of Science ®Google Scholar
• Johnson F, Manning D, Wang C, Stauffer J. Evaluation of naltrexone concentrations following dosing with ALO-01 (morphine sulfate and naltrexone hydrochloride) extended release capsules for 1 year in patients with chronic pain. Poster presented at the 71st Annual Meeting of The College on Problems of Drug Dependence, Reno, NV, USA, 20 – 25 June 2009
   Google Scholar
• Meyer MC, Straughn AB, Lo MW, Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. J Clin Psychiatry 1984;45:15-19
   PubMed Web of Science ®Google Scholar
• Wong DF, Ye W, Zhou Y, In vivo human opiate receptor occupancy of naltrexone: a dose-response analysis. Abstract presented at the 36th Annual Meeting of the Society for Neuroscience, Atlanta, GA, USA, 14 – 18 October 2006
   Google Scholar
• Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs 2003;35:253-9
   PubMed Web of Science ®Google Scholar
• Handelsman L, Cochrane KJ, Aronson MJ, Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse 1987;13:293-308
   PubMed Web of Science ®Google Scholar
• Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA 2002;287:622-7
   PubMed Web of Science ®Google Scholar
• Ruan X, Chen T, Gudin J, Acute opioid withdrawal precipitated by ingestion of crushed Embeda (morphine extended release with sequestered naltrexone): case report and the focused review of the literature. J Opioid Manag 2010;6:300-3
   PubMedGoogle Scholar
• Jang DH, Robe JC, Hoffman RS. Severe opioid withdrawal due to misuse of new combined morphine and naltrexone product (Embeda). Ann Emerg Med 2010;55:303-4
   PubMed Web of Science ®Google Scholar
• Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med 2005;6:107-112
   PubMed Web of Science ®Google Scholar
• Katz NP, Adams EH, Chilcoat H, Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain 2007;23:648-60
   PubMed Web of Science ®Google Scholar
• Katz N. Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep 2008;10:11-18
   PubMedGoogle Scholar
• Lavine G. Abuse deterrence focus of upcoming opioid formulations. Am J Health Syst Pharm 2008;65:381,385
   PubMedGoogle Scholar
• Gershell L, Goater JJ. Making gains in pain. Nat Rev Drug Discov 2006;5:889-90
   PubMed Web of Science ®Google Scholar
• Brennan MJ, Stanos S. Strategies to optimize pain management with opioids while minimizing risk of abuse. PM R 2010;2:544-58
   PubMedGoogle Scholar
• Gourlay DL, Heit HA. Pain and addiction: managing risk through comprehensive care. J Addict Dis 2008;27:23-30
   PubMed Web of Science ®Google Scholar
• Simoni-Wastila L, Tompkins C. Balancing diversion control and medical necessity: the case of prescription drugs with abuse potential. Substance Abuse Misuse 2001;36:1275-96
   Google Scholar
• Butler SF, Budman SH, Licari A, National addictions vigilance intervention and prevention program (NAVIPPRO™): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiol Drug Saf 2008;17:1142-54
   PubMed Web of Science ®Google Scholar
• Cicero TJ, Dart RC, Inciardi JA, The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS). Pain Med 2007;8:157-70
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services. Identification of drug and biological products deemed to have risk evaluation and mitigation strategies for purposes of the Food and Drug Administration Amendments Act of 2007, 2008; Federal Register 73: 16313-4. Available from: http://www.fda.gov/OHRMS/DOCKETS/98fr/E8_6201.pdf [Last accessed 21 February 2011]
   Google Scholar